Skip to main content

Advertisement

Table 1 Analysis of NUCKS immunostaining in non malignant, non metastatic breast lesions

From: NUCKS overexpression in breast cancer

  Fibroepithelial tumours (n=13) Benign epithelial proliferations (n = 31) Intraductal proliferative lesions (n = 38)
Overall NUCKS Immuno- Reactivity Fibroadenoma (n = 13) RR = ns Adenosis (n = 20) RR = ns Sclerosing adenosis (n = 11) R = ns Usual ductal hyperplasia, UDH (n = 16), RR = 1.5 Atypical ductal hyperplasia, ADH, (n = 6), RR = 4.0–5.0 Ductal carcinomas in situ, DCIS (n = 16), RR = 8.0–11.0
Negative (0) 13(100%) 3 (15%) 1 (9%) 3 (19%)   1 (6%)
+1   10 (50%) 6(55%) 8 (50%) 1 (17%) 2 (12%)
+2   6 (30%) 4(36%) 4 (25%) 2 (33%) 6 (38%)
+3   1 (5%)   1 (6%) 3 (50%) 7 (44%)
Low expression (0/+1) 13 (100%) 13 (65%) 7 (64%) 11 (69%) 1 (17%) 3 (18%)
High expression (+2/+3)   7 (35%) 4 (36%) 5 (31%) 5 (83%) 13 (82%)
  1. RR = relative risk for subsequent development of invasive breast cancer; ns = non significant